文献速递传染病防控与疫情报告免疫规划

一种热稳定性干制剂灭活Hikojima全菌/霍乱毒素B亚单位口服霍乱疫苗

A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.
PubMed 文献 · Vaccine · 2023-04-19

为应对现有口服霍乱疫苗需冷链且部分缺乏霍乱毒素B亚单位(CTB)的问题,研究者开发了一种基于福尔马林灭活Hikojima单菌株与低成本重组CTB的冻干疫苗。该疫苗在25°C可保存至少26个月、40°C至少8个月,并保持细胞形态及保护性Ogawa和Inaba脂多糖与CTB不丢失;小鼠中耐受良好,血清和肠黏膜抗体应答与Shanchol和Dukoral相当。

要点

  • 新疫苗为冻干干制剂,可在25°C保存至少26个月、40°C至少8个月。
  • 该疫苗含重组CTB,补充了Shanchol和Euvichol-Plus缺乏的CTB抗原。
  • 小鼠中口服免疫原性与Shanchol和Dukoral相当,耐受良好。

核心结论

  • 该热稳定性干制剂灭活Hikojima全菌/CTB口服霍乱疫苗易于制造且成本低,小鼠中耐受良好,口服免疫原性与Shanchol和Dukoral相当。

研究设计与样本

  • 研究基于福尔马林灭活Hikojima单菌株与低成本重组CTB的冻干混合物开发疫苗,并在小鼠中评估免疫原性。

主要发现

  • 新疫苗在25°C可保存至少26个月,在40°C可保存至少8个月,并保持细胞形态及保护性Ogawa和Inaba脂多糖与CTB不丢失。
  • 小鼠中该疫苗耐受良好,血清和肠黏膜抗体应答与Shanchol和Dukoral口服霍乱疫苗相当。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The feared diarrheal disease cholera remains an important global health problem. Use of oral cholera vaccine (OCV) from a global stockpile against both epidemic and endemic cholera is a cornerstone in the World Health Organisations (WHOs) global program for "Ending cholera by 2030". Three liquid inactivated whole-cell OCVs (Dukoral®, ShancholTM, and Euvichol-Plus®) are WHO prequalified and have proved to be safe and effective. However, their multicomponent composition and cold-chain requirement increase manufacturing, storage and transport costs. ShancholTM and Euvichol-Plus® OCVs used in WHOs global vaccine stockpile also lack the protective cholera toxin B-subunit (CTB) antigen present in Dukoral®, which results in suboptimal efficacy. WHOs Global Task Force on Cholera Control (GTFCC) has identified a thermostable, dry formulation vaccine as a priority for further OCV development. We describe here the development of such a vaccine, based on a lyophilized mixture of a single strain of formalin-killed Hikojima bacteria together with a low-cost, recombinantly produced CTB. The new vaccine, which is easy and inexpensive to manufacture, could be stored for at least 26 months at 25 °C and for at least 8 months at 40 °C with preservation of cell morphology and with no loss of protective Ogawa and Inaba lipopolysaccharides or CTB. It also proved to be well tolerated and to have equivalent oral immunogenicity in mice as ShancholTM and Dukoral® OCVs with regard to both serum and intestinal-mucosal antibody responses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Terrinoni M, Nordqvist SL, Löfstrand M, et al. A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine. Vaccine. 2023. PMID: 37085452. doi:10.1016/j.vaccine.2023.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。